"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained.
Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
S. Chris Malaisrie, MD, professor of surgery at Northwestern University, explained what these data can tell us about the lifetime management of patients who require aortic valve replacement.
Isodose moderately hypofractionated radiotherapy allows patients to undergo just 4-5 weeks of treatment, compared to conventional therapy that can take around 8.
